KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M

* KalVista Pharmaceuticals press release [https://seekingalpha.com/pr/20301475-kalvista-pharmaceuticals-provides-operational-update-and-reports-third-quarter-financial] (KALV [https://seekingalpha.com/symbol/KALV]): Q3 GAAP EPS of -$0.92.
* Revenue of $13.69M.

MORE ON KALVISTA PHARMACEUTICALS

* KalVista: Prophylaxis Is Shrinking The Acute HAE TAM [https://seekingalpha.com/article/4828362-kalvista-prophylaxis-is-shrinking-acute-hae-tam]
* KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4822086-kalvista-pharmaceuticals-inc-kalv-q1-2026-earnings-call-transcript]
* KalVista Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4822062-kalvista-pharmaceuticals-inc-2026-q1-results-earnings-call-presentation]
* KalVista Pharmaceuticals Q3 2026 Earnings Preview [https://seekingalpha.com/news/4519430-kalvista-pharmaceuticals-q3-2026-earnings-preview]
* KalVista prices upsized offering of $125M of 3.250% notes due 2031 [https://seekingalpha.com/news/4498658-kalvista-prices-upsized-offering-of-125m-of-3250-notes-due-2031]